Cargando…

S168: PELABRESIB (CPI-0610) MONOTHERAPY IN PATIENTS WITH HIGH-RISK ESSENTIAL THROMBOCYTHEMIA REFRACTORY OR INTOLERANT TO HYDROXYUREA: PRELIMINARY RESULTS FROM MANIFEST STUDY

Detalles Bibliográficos
Autores principales:	Passamonti, Francesco, Patriarca, Andrea, Knapper, Steven, Rivera, Candido, Scandura, Joseph M, Devos, Timothy, Granacher, Nikki, Mead, Adam, Oh, Stephen, Palmer, Jeanne, Rampal, Raajit K, Teichmann, Lino, LI, Qing, Eliane, Jean-Pierre, Chang, Tzuu-Wang, Klein, Sandra, Colak, Gozde, Harrison, Claire
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428431/ http://dx.doi.org/10.1097/01.HS9.0000967584.99278.43

Ejemplares similares

P1027: UPDATED DURABILITY OF RESPONSE AND SAFETY IN MANIFEST ARM 3: PELABRESIB (CPI-0610) COMBINED WITH RUXOLITINIB FOR JAK INHIBITOR TREATMENT-NAÏVE PATIENTS WITH MYELOFIBROSIS
por: Harrison, Claire, et al.
Publicado: (2023)

P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS
por: Kremyanskaya, Marina, et al.
Publicado: (2023)

A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma
por: Blum, Kristie A., et al.
Publicado: (2022)

P1029: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PELABRESIB (CPI-0610) IN COMBINATION WITH RUXOLITINIB VS RUXOLITINIB OR FEDRATINIB MONOTHERAPY IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS
por: Gupta, V., et al.
Publicado: (2022)

MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis
por: Mascarenhas, John, et al.
Publicado: (2023)

P1030: MANIFEST-2, A GLOBAL, PHASE 3, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROL STUDY OF PELABRESIB (CPI-0610) AND RUXOLITINIB VS PLACEBO AND RUXOLITINIB IN JAK INHIBITOR-NAÏVE MYELOFIBROSIS PATIENTS
por: Harrison, C., et al.
Publicado: (2022)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia
por: Mascarenhas, John, et al.
Publicado: (2022)

P1046: TREATMENT COMPARISON OF HYDROXYUREA VS RUXOLITINIB IN ESSENTIAL THROMBOCYTHEMIA (ET): A MATCHED COHORT ANALYSIS
por: Grunwald, Michael, et al.
Publicado: (2023)

An Ulceronecrotic Foot Lesion in a Patient with Essential Thrombocythemia: Successful Treatment with Hydroxyurea
por: Kato, Tokue, et al.
Publicado: (2012)

Successful Management of Hydroxyurea-induced Leg Ulcers in Essential Thrombocythemia: Report of 3 Cases
por: Rahal, Jihane Abou, et al.
Publicado: (2013)

Interferon alpha therapy in essential thrombocythemia and polycythemia vera - a systematic review and meta-analysis
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2020)

Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high‐risk essential thrombocythemia
por: Park, Young Hoon, et al.
Publicado: (2023)

A Novel Gene vp0610 Negatively Regulates Biofilm Formation in Vibrio parahaemolyticus
por: Jiang, Fufeng, et al.
Publicado: (2021)

Rapid and robust reversion to essential thrombocythemia on treatment with Decitabine in a case of hydroxyurea‐induced t‐MDS/AML
por: Horton, Joshua D., et al.
Publicado: (2015)

PB2215: HYDROXYUREA-INDUCED CUTANEUS ADVERSE EVENTS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

Acquired Melanonychia in Chilean Patients with Essential Thrombocythemia Treated with Hydroxyurea: A Report of 7 Clinical Cases and Review of the Literature
por: Murray, Nigel P., et al.
Publicado: (2013)

CPI Hard Disk System
Publicado: (2017)

Scotch 777 6250 CPI
Publicado: (2017)

Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea
por: Renso, Rossella, et al.
Publicado: (2018)

Your 168
por: Kraemer, Harry
Publicado: (2020)

The Effect of Galangin on the Regulation of Vascular Contractility via the Holoenzyme Reactivation Suppressing ROCK/CPI-17 rather than PKC/CPI-17
por: Yoon, Hyuk-Jun, et al.
Publicado: (2022)

Essential thrombocythemia
por: Brière, Jean B
Publicado: (2007)

Management of thrombocythemia
por: Gowin, Krisstina, et al.
Publicado: (2014)

Fagottsonate, Opus 168 = Bassoon sonata, op. 168
por: Saint-Saëns, Camille, 1835-1921
Publicado: (2010)

3M No. 700 Black Watch 6250 CPI
Publicado: (2017)

The clinical significance of cytoplasmic inclusions(CPI) in synovial fluid examination.
por: Park, J., et al.
Publicado: (1996)

Immunoprofiling of T cell responses in melanoma patients undergoing CPI therapy
por: Talarico, Lee Ann, et al.
Publicado: (2015)

CPI motif interaction is necessary for capping protein function in cells
por: Edwards, Marc, et al.
Publicado: (2015)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017)

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
por: Mora, Barbara, et al.
Publicado: (2019)

Dynamics and Endocytosis of Flot1 in Arabidopsis Require CPI1 Function
por: Cao, Yangyang, et al.
Publicado: (2020)

MCN-CPI: Multiscale Convolutional Network for Compound–Protein Interaction Prediction
por: Wang, Shuang, et al.
Publicado: (2021)

168th RB Meeting
por: CERN. Geneva. Research Board
Publicado: (2004)

On-line experience with the 168/E
por: Carroll, J T, et al.
Publicado: (1981)

Extension of the experiment T 165 + T 168
por: CERN. Geneva. Track Chamber Committee
Publicado: (1972)

Calling RNF168 to action
por: Nowsheen, Somaira, et al.
Publicado: (2018)

AGO1 Homeostasis Involves Differential Production of 21-nt and 22-nt miR168 Species by MIR168a and MIR168b
por: Vaucheret, Hervé
Publicado: (2009)

Emerging treatments for essential thrombocythemia
por: Okoli, Steven, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kbhcan1s8tic9o93ga15ipi9d6